MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

20.05 -3.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.97

Max

20.6

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

89.037

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-8.83% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.18%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

42M

410M

Iepriekšējā atvēršanas cena

23.79

Iepriekšējā slēgšanas cena

20.05

Ziņu noskaņojums

By Acuity

50%

50%

141 / 352 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. janv. 23:49 UTC

Karstas akcijas

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

2026. g. 26. janv. 23:09 UTC

Galvenie tirgus virzītāji

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

2026. g. 26. janv. 23:52 UTC

Tirgus saruna

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

2026. g. 26. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

2026. g. 26. janv. 23:37 UTC

Tirgus saruna

Gold Rises Amid Concerns Over Tariffs -- Market Talk

2026. g. 26. janv. 22:41 UTC

Tirgus saruna

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

2026. g. 26. janv. 22:26 UTC

Peļņas

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

2026. g. 26. janv. 22:26 UTC

Peļņas

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

2026. g. 26. janv. 22:25 UTC

Peļņas

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

2026. g. 26. janv. 22:25 UTC

Peļņas

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

2026. g. 26. janv. 22:25 UTC

Peļņas

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

2026. g. 26. janv. 22:24 UTC

Peļņas

Karoon Energy 4Q Sales Revenue US$156.1 Million

2026. g. 26. janv. 22:23 UTC

Peļņas

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

2026. g. 26. janv. 22:23 UTC

Peļņas

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

2026. g. 26. janv. 22:23 UTC

Peļņas

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

2026. g. 26. janv. 22:22 UTC

Peļņas

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

2026. g. 26. janv. 22:05 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Copper Shareholders Approve Takeover

2026. g. 26. janv. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

2026. g. 26. janv. 21:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2026. g. 26. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 26. janv. 21:34 UTC

Peļņas

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

2026. g. 26. janv. 21:34 UTC

Peļņas

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

2026. g. 26. janv. 21:34 UTC

Peļņas

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

2026. g. 26. janv. 21:34 UTC

Peļņas

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

2026. g. 26. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

2026. g. 26. janv. 21:30 UTC

Peļņas

Nucor 4Q Sales $7.69B >NUE

2026. g. 26. janv. 21:30 UTC

Peļņas

Nucor 4Q Net $378M >NUE

2026. g. 26. janv. 21:30 UTC

Peļņas

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

2026. g. 26. janv. 21:30 UTC

Peļņas

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

2026. g. 26. janv. 21:30 UTC

Peļņas

Nucor 4Q EPS $1.64 >NUE

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-8.83% uz leju

Prognoze 12 mēnešiem

Vidējais 19 USD  -8.83%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

141 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat